Search results: (10000)
News What can we base the decision on for the choice of initial treatment modality for CLL?
We now have a range of highly effective treatment options for patients with chronic lymphocytic leukemia (CLL). New drugs have significantly contributed to improved overall survival (OS). However, there are still questions about the most appropriate treatment regimen or criteria for choosing the initial therapeutic modality. Some of these questions are posed—and answers sought—by Professor John F. Seymour from the University of Melbourne in his recent communication.
News Update of International Recommendations for the Diagnosis and Treatment of Hereditary Angioedema from 2021
The aim of the 2021 update of the recommendations for the diagnosis and treatment of hereditary angioedema (HAE) is to help doctors answer important clinical questions: How to diagnose HAE? When and what prophylactic treatment to administer? What are the treatment goals? How do treatment of children and pregnant women differ? How to monitor disease activity, its impact, and control?
News Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children – Results of the TERIKIDS Study
Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10–17 years in the European Union. The basis for this registration was the favorable results of the TERIKIDS study, which we summarize below. Teriflunomide thus became the first oral medication for 1st line treatment of RRMS in children and adolescents within the EU.
News Safety and Efficacy of Bimekizumab Self-Administration in Psoriasis Patients
Patient adherence to regular administration of biologic therapy is crucial for its effectiveness. The studies presented below evaluated self-administration of the humanized monoclonal antibody against IL-17A and IL-17F, bimekizumab, in patients with plaque psoriasis using a prefilled syringe or autoinjector.
News Safety and Efficacy of Combination Therapy for Allergic Rhinitis Compared to Monotherapies and Placebo
Combination therapy of antihistamine and corticosteroid is a promising alternative for patients suffering from seasonal allergic rhinitis. A phase II clinical study aimed to determine the effective dosage, efficiency, and safety of combination therapy compared to monotherapies and placebo.
News Does empagliflozin improve the overall health of patients with heart failure with reduced LVEF?
A recently published secondary analysis of the EMPEROR-Reduced study is based mainly on the results of the KCCQ-23 questionnaire, which assesses the patient's health status from their perspective. Its goal was to verify whether the benefit of empagliflozin added to the treatment of heart failure with reduced left ventricular ejection fraction (HFrEF) depends on the initial health status and how it subsequently affects the health status of these patients over 1 year.
News Comparison of Dabigatran and Vitamin K Antagonists in Patients with Atrial Fibrillation in Real-World Practice
The final 3-year results of the GLORIA-AF study conducted in real-world practice with patients newly diagnosed with atrial fibrillation show a lower incidence of major bleeding and lower overall mortality with comparably effective prevention of cerebrovascular accidents and myocardial infarction when administering dabigatran compared to vitamin K antagonists (VKAs).
News Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction
The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure or death from cardiovascular (CV) causes in the EMPEROR-Reduced study in patients with adequately treated heart failure with reduced left ventricular ejection fraction (HFrEF) compared to placebo, regardless of whether the patients had diabetes. A post hoc analysis of this study focused on another important question: how does the benefit of adding empagliflozin interact with the standard disease-modifying therapy for heart failure?
News Hydroresponsive Dressings for Acute and Hard-to-Heal Wounds
A recently published review of clinical evidence from nearly three dozen studies demonstrates successful debridement and cleansing of various hard-to-heal wounds using HydroClean hydroresponsive dressing, with favorable healing outcomes.
News Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A
The famous slogan of neurologists in connection with strokes – 'Time is brain!' – can be modified to 'Time is blood!' for the issue of acquired hemophilia A (AHA). The factor of time plays a crucial role in the prognosis of patients with AHA – delayed diagnosis is associated with longer administration of hemostatic treatment, higher risk of relapses, and mortality.
News Overview of the Efficacy of the Fixed Combination Aclidinium-Bromide/Formoterol-Fumarate in the Maintenance Treatment of COPD
Fixed combination inhalation medications have become the cornerstone of pharmacotherapy for moderate to severe chronic obstructive pulmonary disease (COPD). American authors have published an overview of study results evaluating the efficacy and safety of one of the newest fixed combinations of LABA/LAMA, aclidinium-bromide and formoterol-fumarate (AB/FF), in the maintenance treatment of COPD compared to placebo or other medications. These clinical studies investigated the extent to which regular use of this fixed combination alleviates COPD symptoms, improves lung function, reduces the incidence of exacerbations, and increases exercise tolerance.
News Current Challenges in Diagnosing Progressive Fibrotic Interstitial Lung Diseases
A subset of patients with interstitial lung diseases exhibits a progressive fibrotic phenotype associated with a deterioration in quality of life and increased mortality. Early diagnosis and adequate therapy could improve their prognosis, but currently, there are numerous problems and challenges.
News Risks Associated with Higher Residual Concentrations of Dabigatran in Seniors and Their Prevalence
Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The benefit-risk assessment of anticoagulation is individual and depends on many factors. A Dutch observational pilot study examined residual concentrations of dabigatran in seniors of different ages with atrial fibrillation to clarify the relationship between study results and clinical practice.
News Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib
Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect in patients who have developed resistance during treatment with other ALK inhibitors. It has demonstrated efficacy in patients with ALK+ non-small cell lung cancer (NSCLC) who are refractory to crizotinib as well as in ALK+ NSCLC not previously treated with an ALK inhibitor. Post hoc analysis of the ALTA-1L trial, presented as a poster at this year's American Society of Clinical Oncology (ASCO) annual meeting, addresses whether the maximum reduction in target lesions of ALK+ NSCLC treated with brigatinib or crizotinib correlates with overall survival (OS) and progression-free survival (PFS).
News Frequency of Participation in Sports Activities and the Risk of Injury in Children with Hemophilia
In children with hemophilia, numerous positive effects of physical activity on their health have been described. However, due to concerns about injuries and joint bleeding, young hemophiliacs may often be limited in real participation in sports life. Results from published studies, however, indicate that with proper therapy, the frequency of injuries is similar to that of the general population.
News Development of Immune Thrombocytopenia as a Result of Past COVID-19 Illness
Immune thrombocytopenia (ITP) developing secondary to COVID-19 is a completely new experience in clinical practice. A brief summary on this topic, describing incidence and response to treatment, was published last year by authors from Cleveland.
News Assessment of the Effectiveness of Superabsorbent Dressings from the Perspective of Doctors and Patients
The Journal of Wound Care published the results of an observational study on the benefits of Resposorb Super superabsorbent dressings in the treatment of acute and chronic wounds with higher levels of exudate.
News Effect of Romiplostim in Refractory ITP with Possibility of Maintaining Response Without Treatment – Case Report
This case report from the United States features an ideal therapeutic response to romiplostim in a patient with refractory immune thrombocytopenia (ITP). After several years of successful therapy, the medication could even be gradually discontinued while maintaining the therapeutic response.
News What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?
Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20 years, studies have linked obesity to higher incidences of breast and colorectal cancers, as well as hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD). What is the efficacy and safety of sorafenib in this patient population, and does it differ from patients with liver cancers caused by viral infection or alcohol abuse? This intrigued a team of researchers from Melbourne, Australia.
News Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis
Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic parameters in individuals with the first episode of psychosis. Moreover, it significantly increased during 1 year after this episode.
News Efficacy of Conventional and Intensified Lifestyle Interventions in Individuals with Prediabetes According to Risk Level
Lifestyle changes can prevent the development of type 2 diabetes in individuals with prediabetes, but according to current findings, these measures fail for a significant portion of study participants. In the Diabetes Prevention Program (DPP) study, one in five patients in the lifestyle intervention group developed type 2 diabetes within 4 years. However, there are individuals with prediabetes who do not develop diabetes without lifestyle intervention even after 11 years of follow-up. This indicates the need to create more precisely stratified intervention strategies based on the identification of high-risk (HR) and low-risk (LR) individuals with prediabetes. This is precisely the focus of a recently published study by German authors.
News Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation factor VIII (FVIII) concentrate. Recently, some hemophiliacs have also been switched to prophylaxis with so-called non-factor therapy, specifically emicizumab. A recently published report from the USA shows a comparison of these two modalities in real clinical practice.
News The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
We summarize the results of a clinical study on the effect of probiotics containing Limosilactobacillus reuteri on the improvement of gingivitis in patients with diabetes. It has been proven that the supplementary administration of L. reuteri statistically significantly improves gum health and helps to suppress gingival inflammation.
News Position of Enoxaparin and DOACs in Extended Prevention of VTE After Surgeries for Gynecological Malignancies
The prophylaxis of venous thromboembolism is a crucial part of postoperative management in oncological diseases, including gynecological malignancies. A newly published survey study conducted in Australia and New Zealand focused precisely on these. The authors were interested in different types of postoperative prophylactic regimens and the potential use of direct oral anticoagulants (DOACs) in them.
News Safety of Tofacitinib in Ulcerative Colitis – Combined Results of 6 Studies
At the annual meeting of the American Gastroenterological Association (ACG) in October 2023 in Vancouver, Canada, the results of the final safety analysis of tofacitinib in the treatment of ulcerative colitis from a clinical trial program involving 1,157 patients with exposure duration to this therapy of up to 9.2 years were presented.